Skip to main content
SpringerLink
Log in

Cyclins and Breast Cancer

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

The D-type and E-type cyclins control the G1 to S phase transition during normal cell cycle progression and are critical components of steroid- and growth factor-induced mitogenesis in breast epithelial cells. Mammary epithelial cell-specific overexpression of these genes leads to mammary carcinoma, while in cyclin D1-deficient mice mammary gland development is arrested prior to lobuloalveolar development. Cyclin D1 null mice are resistant to mammary carcinoma induced by the neu and ras oncogenes, indicating an essential role for cyclin D1 in the development of some mammary cancers. Cyclin D1 and E1 are commonly overexpressed in primary breast cancer, with some evidence of an association with an adverse patient outcome. This observation may result in part from their ability to confer resistance to endocrine therapies. The functional consequences of cyclin E overexpression in breast cancer are likely related to its role in cell cycle progression, whereas that of cyclin D1 may also be a consequence of a more recently defined role in transcriptional regulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. D. Hanahan and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100:57–70.

    Google Scholar 

  2. M. Malumbres and M. Barbacid (2001). To cycle or not to cycle: A critical decision in cancer. Nat. Rev. Cancer 1:222–231.

    Google Scholar 

  3. C. J. Ormandy, E. A. Musgrove, R. Hui, R. J. Daly, and R. L. Sutherland (2003). Cyclin D1, EMS1 and 11q13 amplification in human breast cancers. Breast Cancer Res. Treat. 78:323–335.

    Google Scholar 

  4. M. F. Buckley, K. J. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127–2213.

    Google Scholar 

  5. K. Keyomarsi and A. B. Pardee (1993). Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90:1112–1116.

    Google Scholar 

  6. C. Gillett, V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, et al. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812–1817.

    Google Scholar 

  7. K. M. Alle, S. M. Henshall, A. S. Field, and R. L. Sutherland (1998). Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin. Cancer Res. 4:847–854.

    Google Scholar 

  8. K. Keyomarsi, N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, A. B. Pardee, and E. Cyclin (1994). A potential prognostic marker for breast cancer. Cancer Res. 54:380–385.

    Google Scholar 

  9. M. Loden, M. Sighall, N. H. Nielsen, G. Roos, S. O. Emdin, H. Ostlund, et al. (2002). The cyclin D1 high and cyclin E high subgroups of breast cancer: Separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21:4680–4690.

    Google Scholar 

  10. R. Hui, A. L. Cornish, R. A. McClelland, J. F. Robertson, R. W. Blamey, E. A. Musgrove, et al. (1996). Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin. Cancer Res. 2:923–928.

    Google Scholar 

  11. Y. Geng, W. Whoriskey, M. Y. Park, R. T. Bronson, R. H. Medema, T. Li, et al. (1999). Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97:767–777.

    Google Scholar 

  12. D. O. Morgan (1995). Principles of CDK regulation. Nature 374:131–134.

    Google Scholar 

  13. C. J. Sherr and J. M. Roberts (1999). CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512.

    Google Scholar 

  14. N. Dyson (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245–2262.

    Google Scholar 

  15. J. LaBaer, M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, et al. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847–862.

    Google Scholar 

  16. E. A. Musgrove, J. A. Hamilton, C. S. Lee, K. J. Sweeney, C. K. Watts, and R. L. Sutherland (1993). Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577–3587.

    Google Scholar 

  17. J. Lukas, J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, et al. (1995). Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125–2134.

    Google Scholar 

  18. R. J. Fiddes, P. W. Janes, S. P. Sivertsen, R. L. Sutherland, E. A. Musgrove, and R. J. Daly (1998). Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene 16:2803–2813.

    Google Scholar 

  19. G. A. Colditz (1998). Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90:814–823.

    Google Scholar 

  20. O. W. Prall, B. Sarcevic, E. A. Musgrove, C. K. Watts, and R. L. Sutherland (1997). Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272:10882–10894.

    Google Scholar 

  21. J. S. Foster and J. Wimalasena (1996). Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10:488–498.

    Google Scholar 

  22. L. Altucci, R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, and M. Truss et al. (1996). 17b-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 12:2315–2324.

    Google Scholar 

  23. M. D. Planas-Silva and R. A. Weinberg (1997). Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:4059–4069.

    Google Scholar 

  24. J. Lukas, J. Bartkova, and J. Bartek (1996). Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16:6917–6925.

    Google Scholar 

  25. O. W. Prall, E. M. Rogan, E. A. Musgrove, C. K. Watts, and R. L. Sutherland (1998). c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol. 18:4499–4508.

    Google Scholar 

  26. O. W. Prall, J. S. Carroll, and R. L. Sutherland (2001). A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E-Cdk2. J. Biol. Chem. 276:45945–45951.

    Google Scholar 

  27. A. L. Gartel, X. Ye, E. Goufman, P. Shianov, N. Hay, and F. Najmabadi et al. (2001). Myc represses the p21WAF1/CIP1 promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U.S.A. 98:4510–4515.

    Google Scholar 

  28. E. A. Musgrove, A. Swarbrick, C. S. Lee, A. L. Cornish, and R. L. Sutherland (1998). Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1812–1825.

    Google Scholar 

  29. A. Swarbrick, C. S. Lee, R. L. Sutherland, and E. A. Musgrove (2000). Cooperation of p27Kip1 and p18INK4c in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20:2581–2591.

    Google Scholar 

  30. R. L. Sutherland, R. E. Hall, and I. W. Taylor (1983). Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 43:3998–4006.

    Google Scholar 

  31. C. K. Watts, A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland (1995). Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9:1804–1813.

    Google Scholar 

  32. J. S. Carroll, O. W. Prall, E. A. Musgrove, and R. L. Sutherland (2000). A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275:38221–38229.

    Google Scholar 

  33. S. Cariou, J. C. Donovan, W. M. Flanagan, A. Milic, N. Bhattacharaya, and J. M. Slingerland (2000). Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97:9042–9046.

    Google Scholar 

  34. J. S. Carroll, A. Swarbrick, E. A. Musgrove, and R. L. Sutherland (2002). Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: Implications for the antiproliferative effects of antiesgrogens. Cancer Res. 62:3126–3131.

    Google Scholar 

  35. J. S. Carroll, D. K. Lynch, A. Swarbrick, J.-M. Renoir, B. Sarcevic, R. J. Daly, et al. (2003). p27Kip1 induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res. 63:4322–4326.

    Google Scholar 

  36. J. C. Donovan, A. Milic, and J. M. Slingerland (2001). Constitutive MEK/MAPK acrtivation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276:40888–40895.

    Google Scholar 

  37. M. Venditti, B. Iwasiow, F. M. Orr, and P. C. Shiu (2002). C-myc gene expression alone is sufficent to confer resistance to antiestrogen in human breast cancer cells. Int. J. Cancer 99:35–42.

    Google Scholar 

  38. R. Hui, G. Finney, J. S. Carroll, C. S. Lee, E. A. Musgrove, and R. L. Sutherland (2002). Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiesgrogens in T-47D breast cancer cells. Cancer Res. 62:6916–6923.

    Google Scholar 

  39. E. A. Musgrove, L. J. Hunter, C. S. Lee, A. Swarbrick, R. Hui, and R. L. Sutherland (2001). Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27Kip1 association with cyclin E-Cdk2. J. Biol. Chem. 276:47675–47683.

    Google Scholar 

  40. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669–671.

    Google Scholar 

  41. W. J. Muller, E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115.

    Google Scholar 

  42. E. Sinn, W. J. Muller, P. K. Pattengale, I. Tepler, R. Wallace, and P. Leder (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465–475.

    Google Scholar 

  43. T. A. Stewart, P. K. Pattengale, and P. Leder (1984). Spontaneous mammary adenocarcinomas in trangenic mice that carry and express MTV/myc fusion genes. Cell 38:627–637.

    Google Scholar 

  44. M. Gadd, C. Pisc, J. Branda, V. Ionescu-Tiba, Z. Nikolic, C. Yang, et al. (2001). Regulation of cyclin D1 and p16INK4A is critical for growth arrest during mammary involution. Cancer Res. 61:8811–8819.

    Google Scholar 

  45. G. Kong, S. S. Chua, Y. Yijun, F. Kittrell, R. C. Moraes, D. Medina, et al. (2002). Functional analysis of cyclin D2 and p27Kip1 in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21:7214–7225.

    Google Scholar 

  46. E. Evron, C. B. Umbricht, D. Korz, V. Raman, D. M. Loeb, B. Niranjan, et al. (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61:2782–2787.

    Google Scholar 

  47. M. A. Ciemerych, A. M. Kenney, E. Sicinska, I. Kalaszczynska, R. T. Bronson, and D. H. Rowitch, et al. (2002). Development of mice expressing a single D-type cyclin. Genes Dev. 16:3277–3289.

    Google Scholar 

  48. K. J. Sweeney, B. Sarcevic, R. L. Sutherland, and E. A. Musgrove (1997). Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 14:1329–1340.

    Google Scholar 

  49. A. Russell, M. A. Thompson, J. Hendley, L. Trute, J. Armes, and D. Germain (1999). Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18:1983–1991.

    Google Scholar 

  50. A. Pirkmaier, R. Dow, S. Ganiatsas, P. Waring, K. Warren, A. Thompson, et al. (2003). Alternative mammary oncogenic pathways are induced by D-type cyclins: MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 22:4425–4443.

    Google Scholar 

  51. D. M. Bortner and M. P. Rosenberg (1997). Induction of mammary gland hyperplasia and carcinomas in trangenic mic expressing human cyclin E. Mol. Cell. Biol. 17:453–459.

    Google Scholar 

  52. P. Sicinski, J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621–630.

    Google Scholar 

  53. V. Fantl, G. Stamp, A. Andrews, I. Rosewell, and C. Dickson (1995). Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364–2372.

    Google Scholar 

  54. W. Tong and J. W. Pollard (2001). Genetic evidence for the interactions of cyclin D1 and p27(Kip1). in mice. Mol. Cell. Biol. 21:1319–1328.

    Google Scholar 

  55. Y. Geng, Q. Yu, E. Sicinska, M. Das, R. T. Bronson, and P. Sicinski (2001). Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98:194–199.

    Google Scholar 

  56. Q. Yu, Y. Geng, and P. Sicinski (2001). Specific protection against breast cancer by cyclin D1 ablation. Nature 411:1017–1021.

    Google Scholar 

  57. P. Jansen-Durr, A. Meichle, P. Steinder, M. Pagano, K. Finke, J. Botz, et al. (1993). Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. U.S.A. 90:3685–3689.

    Google Scholar 

  58. K. V. Desai, N. Xiao, W. Want, L. Gangi, J. Greene, J. I. Powell, et al. (2002). Initiating oncogenic event determines gene-expression patterns of human breast cancer models. PNAS 99:6967–6972.

    Google Scholar 

  59. D. M. Barnes and C. E. Gillett (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52:1–15.

    Google Scholar 

  60. D. Weinstat-Saslow, M. J. Merino, R. E. Manrow, J. A. Lawrence, R. F. Bluth, K. D. Wittenbel, et al. (1995). Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1257–1260.

    Google Scholar 

  61. T. Oyama, K. Kashiwabara, K. Yoshimoto, A. Arnold, and F. Koerner (1998). Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 58:2876–2880.

    Google Scholar 

  62. C. Gillett, P. Smith, W. Gregory, M. Richards, R. Millis, G. Peters, et al. (1996). Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 69:92–99.

    Google Scholar 

  63. R. Michalides, P. Hageman, H. van Tinteren, L. Houben, E. Wientjens, R. Klompmaker, et al. (1996). A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 73:728–734.

    Google Scholar 

  64. G. G. McIntosh, J. J. Anderson, I. Milton, M. Steward, A. H. Parr, M. D. Thomas, et al. (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885–891.

    Google Scholar 

  65. R. Seshadri, C. S. Lee, R. Hui, K. McCaul, D. J. Horsfall, and R. L. Sutherland (1996). Cyclin D1 application is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res. 2:1177–1184.

    Google Scholar 

  66. E. M. Berns, J. A. Foekens, I. L. van Staveren, W. L. van Putten, H. Y. de Koning, H. Portengen, et al. (1995). Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11–18.

    Google Scholar 

  67. I. Bieche, M. Olivi, C. Nogues, M. Vidaud, and R. Lidereau (2002). Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer 86:580–586.

    Google Scholar 

  68. T. S. Hwang, H. S. Han, Y. C. Hong, H. J. Lee, and N. S. Paik (2003). Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol. Int. 53:74–80.

    Google Scholar 

  69. F. S. Kenny, R. Hui, E. A. Musgrove, J. M. Gee, R. W. Blamey, R. I. Nicholson, et al. (1999). Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5:2069–2076.

    Google Scholar 

  70. S. Han, K. Park, B. N. Bae, K. H. Kim, H. J. Kim, Y. D. Kim, et al. (2003). Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol. Rep. 10:141–144.

    Google Scholar 

  71. K. Keyomarsi, S. L. Tucker, T. A. Buchholz, M. Callister, Y. Ding, G. N. Hortobagyi, et al. (2002). Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347:1566–1575.

    Google Scholar 

  72. P. N. Span, V. C. Tjan-Heijnen, P. Manders, L. V. Beex, and C. G. Sweep (2003). Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898–4904.

    Google Scholar 

  73. P. L. Porter, K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, et al. (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222–225.

    Google Scholar 

  74. E. A. Musgrove, C. S. Lee, M. F. Buckley, and R. L. Sutherland (1994). Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 91:8022–8026.

    Google Scholar 

  75. K. J. Sweeney, A. Swarbrick, R. L. Sutherland, E. A. Musgrove (1998). Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16:2865–2878.

    Google Scholar 

  76. R. M. Zwijsen, E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, and R. J. Michalides (1997). CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405–415.

    Google Scholar 

  77. E. Neuman, M. H. Ladha, N. Lin, T. M. Upton, S. J. Miller, J. DiRenzo, et al. (1997). Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 17:5338–5347.

    Google Scholar 

  78. J. Lamb, S. Ramaswamy, H. L. Ford, B. Contreras, R. V. Martinez, F. S. Kittrell, et al. (2003). A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114:323–334.

    Google Scholar 

  79. O. Coqueret (2002). Linking cyclins to transcriptional control. Gene 299:35–55.

    Google Scholar 

  80. J. Lamb, M. H. Ladha, C. McMahon, R. L. Sutherland, and M. E. Ewen (2000). Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol. Cell. Biol. 20:8667–8675.

    Google Scholar 

  81. C. A. Zahnow, P. Younes, R. Laucirica, and J. M. Rosen (1997). Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J. Natl. Cancer Inst. 89:1887–1891.

    Google Scholar 

  82. A. Yamamoto, Y. Hashimoto, K. Kohri, E. Ogata, S. Kato, K. Ikeda, et al. (2000). Cyclin E as a coactivator of the androgen receptor. J. Cell Biol. 150:873–880.

    Google Scholar 

  83. C. Geisen and T. Moroy (2002). The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J. Biol. Chem. 277:39909–39918.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, Sydney, Australia

    Robert L. Sutherland & Elizabeth A. Musgrove

Authors
  1. Robert L. Sutherland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth A. Musgrove
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Sutherland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sutherland, R.L., Musgrove, E.A. Cyclins and Breast Cancer. J Mammary Gland Biol Neoplasia 9, 95–104 (2004). https://doi.org/10.1023/B:JOMG.0000023591.45568.77

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:JOMG.0000023591.45568.77

Search

Navigation